List view / Grid view
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.
New research has categorised hundreds of cancers based on their common protein mutations, highlighting cell components and tumour microenvironments as possible new therapy targets.
A new study has presented a potential strategy for a universal human cancer vaccine. This article delves into the researchers’ findings, exploring their methodologies and results.
A study has demonstrated that dendritic cells play a key role in inflammation and how TNF inhibitors can prevent them from fighting infections.
Central to reproducibility in biomedical research is the ability to use well-characterised and defined reagents. The CPTAC Antibody Portal serves as a National Cancer Institute community resource that provides access to many standardised renewable affinity reagents to cancer-associated targets and accompanying characterisation data. Nikki Withers spoke to Dr Tara Hiltke…
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
A new chemical tool has been used to identify hundreds of modified proteins which allows new insights to major diseases.
CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision and care. Quantitative polymerase chain reaction (qPCR) has thus far been the stalwart technique for providing a check on copy numbers, but here Ping Jin explains why droplet digital PCR…
A new mechanism has been reported for detecting foreign material during early immune responses which may help detect elusive cancers.
Researchers have found that the TRAP-alpha insulin biosynthesis pathway is essential in both cancer and diabetes, with a common primordial ancestor discovered in C. elegans.
The new screening technique may enable development of novel combination-immunotherapy regimens against cancers and persistent infections.
A study has demonstrated that a novel vaccine design for pancreatic cancer has been successful in mice, doubling survival time.
A new signalling pathway has been identified that may help further the understanding of blood clot formation in cancer patients and presents a new drug target for reducing cancer-associated complications.
Researchers have created a new high-throughput screening system which could identify new drugs by focusing on nucleotide metabolism.
A novel computational method has led to the discovery of genes whose alteration may contribute to cancer susceptibility and may lead to new therapeutic targets for cancers.
